Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death‐ligand 1 inhibitors in non–small cell lung cancer
Cancer · 2023
DOI: 10.1002/cncr.34683 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer, 2023. Verfasst von Liza C Villaruz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
The availability of agents targeting the programmed cell death protein 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) immune checkpoint has transformed treatment of advanced and/or metastatic non–small cell lung cancer (NSCLC). However, a substantial proportion of patients treated with these agents do not respond or experience only a brief period of clinical benefit. Even among those whose disease responds, many subsequently experience disease progression. Consequently, novel approaches are needed that enhance antitumor immunity and counter resistance to PD‐(L)1 inhibitors, thereby improving and/or prolonging responses and patient outcomes, in both PD‐(L)1 inhibitor‐sensitive and inhibitor‐resistant NSCLC. Mechanisms contributing to sensitivity and/or resistance to PD‐(L)1 inhibitors in NSCLC include upregulation of other immune checkpoints and/or the presence of an immunosuppressive tumor microenvironment, which represent potential targets for new therapies. This review explores novel therapeutic regimens under investigation for enhancing responses to PD‐(L)1 inhibitors and countering resistance, and summarizes the latest clinical evidence in NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology/Oncology, Department of Medicine, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
- Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- The Ohio State University-James Comprehensive Cancer Center, Columbus, Ohio, USA.
- Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.
ORCID-Profile: Liza C Villaruz
Förderung
- NCI NIH HHS
Zitieren
APA
Villaruz, L. C., Blumenschein, G. R., Otterson, G. A., & Leal, T. A. (2023). Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death‐ligand 1 inhibitors in non–small cell lung cancer. Cancer. https://doi.org/10.1002/cncr.34683
Vancouver
Villaruz LC, Blumenschein GR, Otterson GA, Leal TA. Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death‐ligand 1 inhibitors in non–small cell lung cancer. Cancer. 2023. doi:10.1002/cncr.34683
BibTeX
@article{Villaruz2023,
author = {Villaruz, Liza C and Blumenschein, George R and Otterson, Gregory A and Leal, Ticiana A},
title = {Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death‐ligand 1 inhibitors in non–small cell lung cancer},
journal = {Cancer},
year = {2023},
doi = {10.1002/cncr.34683}
}
EUVIMED